GGrantIndex
Sort

82,697 grants matching vaccine development

Improving predictive capacity of models for universal influenza vaccine development

$775,342
Richard John Webby · St. Jude Children'S Research Hospital · R01 · FY2022 · AI

Cellular and molecular programming of lung resident T cell memory

$775,320
Jacob E Kohlmeier · Emory University · R35 · FY2021 · HL

Preclinical development of human CMV vaccines

$775,296
Michael A McVoy · Virginia Commonwealth University · R01 · FY2013 · AI

Innate immune mechanisms of virologic control and recovery from flavivirus encephalitis

$775,277
Robyn S Klein · Washington University · R56 · FY2020 · AI

Spontaneous and Induced B cell and T cell responses in Alzheimer's Disease

$775,250
Marco Colonna · Washington University · R01 · FY2024 · AG

Targeting tonsillar B cells for the induction of effective mucosal immunity to HIV

$775,239
James J Kobie · University Of Rochester · R01 · FY2017 · DE

Cellular and molecular programming of lung resident T cell memory

$775,223
Jacob E Kohlmeier · Emory University · R35 · FY2022 · HL

Systems-level identification of host determinants of patient outcomes in Lassa fever and Ebola

$775,214
Robert F Garry · Scripps Research Institute, The · U19 · FY2019 · AI

Characterization of Genomics and Metabolomics among Individuals Highly-Exposed, but resistant to Mtb Infection

$775,211
Neel Rajnikant Gandhi · Emory University · R01 · FY2021 · AI

The Impact of Systemic Immunosuppression on RSV Antibody Generation and Effector Functions After Vaccination

$775,187
Andrew Hoover Karaba · Johns Hopkins University · R01 · FY2025 · AI

Antibody-based countermeasures against fentanyl and its analogues

$775,120
Marco Pravetoni · University Of Minnesota · U01 · FY2021 · DA

Vector Biological Studies in Leishmaniasis

$775,112
David Sacks · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI

IMMUNE REGULATION AND VACCINE DEVELOPMENT IN LEISHMANIASIS

$775,112
David Sacks · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI

Efficacy of Oral CMV/SIV Vectors

$775,096
Louis J. Picker · Oregon Health & Science University · R01 · FY2015 · DE

Mali International Center for Excellence in Research: Parasitic Infectious Diseases and their Vectors

$775,082
Carole Long · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI

Cellular and molecular programming of lung resident T cell memory

$775,038
Jacob E Kohlmeier · Emory University · R35 · FY2020 · HL

An Expanded Multivalent Vaccine to Prevent MDR Shigella and ETEC Disease

$775,033
Eileen M. Barry · University Of Maryland Baltimore · U19 · FY2020 · AI

Factors Contributing To Immune-Enhanced Disease In The Pathogenesis of RSV

$775,000
Barney Scott Graham · Niaid Extramural Activities · Z01 · FY2007 · AI

The effect of HIV exposure and infection on immunity to TB in children

$774,996
Grace C John-Stewart · University Of Washington · R01 · FY2023 · AI

How antigen exposure shapes the subsequent NK cell response to HIV

$774,994
Silke Paust · Jackson Laboratory · R01 · FY2025 · AI

Cooperative Research Partnership for an Amebic Colitis Vaccine

$774,980
William A Petri · University Of Virginia · U01 · FY2007 · AI

Pathogenesis and Vaccine Studies Of Simian Immunodeficiency Virus Infection Of Monkeys

$774,959
Vanessa M. Hirsch · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI

The effect of HIV exposure and infection on immunity to TB in children

$774,910
Grace C John-Stewart · University Of Washington · R01 · FY2022 · AI

DNA Vaccine for Seasonal & Pandemic Influenza

$774,843
Deborah L. Fuller · University Of Washington · U01 · FY2010 · AI

Cellular and molecular programming of lung resident T cell memory

$774,830
Jacob E Kohlmeier · Emory University · R35 · FY2023 · HL